WO2013175270A1 - Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée - Google Patents

Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée Download PDF

Info

Publication number
WO2013175270A1
WO2013175270A1 PCT/IB2012/052645 IB2012052645W WO2013175270A1 WO 2013175270 A1 WO2013175270 A1 WO 2013175270A1 IB 2012052645 W IB2012052645 W IB 2012052645W WO 2013175270 A1 WO2013175270 A1 WO 2013175270A1
Authority
WO
WIPO (PCT)
Prior art keywords
strontium ranelate
formula
monohydrate
preparation
octahydrate
Prior art date
Application number
PCT/IB2012/052645
Other languages
English (en)
Inventor
Ravishankar Balasubramaniam
Pulla Rao Polsani
Madduleti TOGATA
Original Assignee
Fleming Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fleming Laboratories Limited filed Critical Fleming Laboratories Limited
Priority to PCT/IB2012/052645 priority Critical patent/WO2013175270A1/fr
Publication of WO2013175270A1 publication Critical patent/WO2013175270A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid

Definitions

  • the present invention relates to an improved process for the preparation of pure strontium ranelate hydrates (la-c) by using the intermediates, amino dimethyl ester of formula-ll and tetramethylester of formula-Ill, which are prepared by novel methods. And also the present invention relates to a new crystalline polymorphic form of strontium ranelate monohydrate and process for the preparation thereof.
  • Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone fragility.
  • the clinical consequences of osteoporosis are vertebral and peripheral fractures. Osteoporosis is common in women after menopause and results an accelerated rate of bone loss. Thus, there is an increase in bone turnover which results decrease in bone mass and bone mineral density.
  • Strontium ranelate is the only an anti-osteoporotic agent which helps in both increasing bone formation and reducing bone resorption, resulting in a rebalance of bone turnover in favour of bone formation. Therefore strontium ranelate is considered as an important medicament in bone disorder diseases and it is marketed as protelos.
  • Strontium ranelate is a distrontium salt of ranelic acid and the chemical name is: distrontium 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophene carboxylic acid, represented as formula-l.
  • EP0415850 provides the processes for the preparation of bivalent salts of ranelic acid, including strontium ranelate, and their therapeutic use.
  • preparation of strontium ranelate hydrates like octahydrate, heptahydrate and tetrahydrate are reported but purity of the products are not mentioned.
  • US Patent No.7105683 provides preparation of amino diester of formula-ll, an intermediate for the preparation of strontium ranelate, by reacting 1 ,3- acetone carboxylic acid dimethyl ester, malononitrile and sulfur in methanol medium in presence of a base - morpholine.
  • US Patent No.7091364 provides process for the preparation of tetraester, methyl 5-[bis(2-methoxy-2-oxoethyl)amino]-4-cyano-3-(2-methoxy-2-oxoethyl)-2- thiophenecarboxylate of formul-ll l, which is another intermediate of strontium ranelate.
  • the process involves reaction of methyl 5-amino-4-cyano-3-(2-methoxy-2-oxoethyl)-2- thiophenecarboxylate of formula-ll with methyl or ethyl bromoacetate in an organic solvent, in presence of potassium carbonate and a catalyst C 8 -Ci 0 type quaternary ammonium salt.
  • US Patent No.7214805 provides the processes for the preparation of intermediates of formula-ll and formula-Ill and also strontium ranelate octahydrate.
  • the intermediates, amino diester of formula-l l and tetra ester of formula-Ill are prepared by adopting the methods described in US patents, US7105683 and US7091364 respectively, whereas strontium ranelate octahydrate is prepared by heating tetraester of formula-Il l with strontium hydroxide in water medium.
  • PCT Publication No.WO2010/021000 also provides the processes for the preparation of intermediates of formula-l l and formula-I ll and also strontium ranelate octahydrate.
  • intermediates as well as strontium ranelate octahydrate are described and the details are as follows: amino diester of formula-ll is prepared by reacting 1 ,3-acetone dicarboxylic acid dimethyl ester, malononitrile and sulfur in methanol medium by using a different base, imidazole, in place of morpholine.
  • Tetra ester of formula-Il l is prepared by reacting amino diester of formula-ll with ethyl bromoacetate in a mixture of organic solvents like acetonitrile and dimethyl sulfoxide or acetone and dimethyl sulfoxide in presence of potassium iodide and potassium carbonate.
  • Strontium ranelate octahydrate is prepared via lithium salt by reacting tetra ester of formula-Il l with aqueous lithium hydroxide in tetrahydrofuran medium followed by addition of strontium chloride.
  • the methodology is having certain disadvantages like usage of mixture of solvents in preparation tetraester of formula-Ill and class-ll solvent, tetrahydrofuran, in active pharmaceutical ingredient (API) formation stage.
  • US Patent No.7459568 discloses the process for the preparation of alpha crystalline form of strontium ranelate, which involves refluxing strontium ranelate octahydrate in water, followed by filtration and drying to give a crystalline strontium ranelate.
  • WO2010/034806 preparations of anhydrate and monohydrate forms of strontium ranelate have been described.
  • This publication provides process for the preparation of an anhydrate/amorphous and monohydrate form of strontium ranelate, which involves suspending a known hydrate - tetrahydrate or octahydrate form of strontium ranelate in an organic solvent, heating the suspension under reflux, cooling the suspension, recovering the solid and drying the solid to obtain crystalline strontium ranelate, and optionally converting the crystalline form into an amorphous form of strontium ranelate.
  • the water content of the resulting hydrates is measured by loss on drying (LOD) analysis and the crystalline and amorphous forms are identified by X-ray powder diffraction measurements.
  • LOD loss on drying
  • the present invention relates to the process for preparation of a new crystalline strontium ranelate monohydrate form obtained by careful dehydration of octahydrate of strontium ranelate.
  • the dehydration process carried out by heating the strontium ranelate octahydrate at about 80-120°C and more specifically at 90-100°C under vacuum in a rotocone dryer to provide a crystalline strontium ranelate monohydrate.
  • the strontium ranelate monohydrate obtained in the present invention is an high purity product with less hygroscopicity and excellent stability. Therefore the obtained product by the present invention can advantageously be used in pharmaceutical compositions due to its high quality factors.
  • the strontium ranelate monohydrate obtained in the present invention is found to be a new crystalline polymorphic form of monohydrate of strontium ranelate.
  • This new crystalline polymorph is characterized by X-ray powder diffraction pattern (XRD) and thermo gravimetric analysis (TGA).
  • XRD pattern of strontium ranelate monohydrate obtained by the present invention is different from that of mentioned in the prior art, disclosed in PCT Publication No.WO2010/034806. Therefore the crystalline form of present invention is considered as a new polymorph of strontium ranelate monohydrate, designated as Polymorph-F, which is represented by formula-lc.
  • One aspect of the present invention provides a novel process for the preparation of amino diester of formula-ll by using an alternative, cheap and commercially available base- triethyl amine.
  • Another aspect of the present invention provides an economical process for the preparation of tetra ester of formula-Ill by using a cheap and commercially available catalyst- cetrimide.
  • the octahydrate of strontium ranelate theoretically has a water content of 21 .90 wt.%, the tetrahydrate of 12.29 wt.% and the monohydrate of 3.38 wt.% and all these forms are presented in this invention.
  • Another important aspect of the present invention provides processes for preparation of high quality active pharmaceutical ingredients (APIs), strontium ranelate octahydrate represented by the formula-la, tetrahydrate represented by the formula-lb and monohydrate represented by the formula-lc.
  • APIs active pharmaceutical ingredients
  • strontium ranelate octahydrate represented by the formula-la tetrahydrate represented by the formula-lb
  • monohydrate represented by the formula-lc The APIs obtained by the present process is excellent in chemical purity, more than 99.80% by HPLC, and with substantially free from impurities.
  • the present invention provides processes to obtain a very pure APIs which are matching all the quality attributes as per the pharmaceutical and ICH guidelines.
  • the octahydrate is by weight of water from about 21 .0 wt. % to about 23.50 wt.%, more preferably from about 22.0 wt.% to about 23.0 wt.% and most preferably from about 21 .50 wt.% to about 22.50 wt.%
  • strontium ranelate tetrahydrate is by weight of water from about 1 1 .0 wt.% to about 13.0 wt.%, more preferably from about 1 1 .50 wt.% to about 12.50 wt.% and most preferably from about 12.0 wt.% to about 12.50 wt.%
  • strontium ranelate monohydrate is by weight of water from about 2.50 wt.% to about 5.0 wt.%, more preferably from about 3.0 wt.% to about 4.0 wt.% and most preferably from about 3.20 wt.%
  • Another aspect of the present invention provides a process for the preparation of crystalline strontium ranelate monohydrate Form-F with a water content of about 3.2 wt.% to 3.8 wt.%, which is related to a monohydrate.
  • Another aspect of the present invention provides strontium ranelate monohydrate Form-F having purity more than 99.85% as measured by HPLC
  • the present invention further provides strontium ranelate hydrates obtained by the processes herein described are having negligible residual organic solvents or organic volatile impurities, which are below than limits recommended for active pharmaceutical ingredients as set forth in ICH guidelines.
  • Figure-1 depicts X-ray powder pattern diffractogram (XRPD) of crystalline strontium ranelate octahydrate.
  • Figure-2 depicts X-ray powder pattern diffractogram (XRPD) of crystalline strontium ranelate tetrahydrate.
  • Figure-3 depicts X-ray powder pattern diffractogram (XRPD) of Form-F of crystalline strontium ranelate monohydrate.
  • Figure-4 depicts thermogram of (TGA) of Form-F of crystalline strontium ranelate monohydrate.
  • Powder XRD of the samples were determined by using X-ray Difractometer, PANanytical, X'pert PRO, X'celerator, X-ray tube with Cu target anode, Divergence slits 15, Receiving slit 0.10mm, Scatter slit 1 °, Power: 45 KV, 40 mA, Scanning speed: 2.122 deg/min,Wave length: 1.5406A.
  • TGA of the samples were determined by using Instrument: TA Instruments,
  • the present invention provides an improved and a cost effective industrial process for the preparation of high pure strontium ranelate hydrates like strontium ranelate octahydrate (la), strontium ranelate tetrahydrate (lb) and strontium ranelate monohydrate (lc).
  • the present invention provides strontium ranelate octahydrate and other hydrates obtained by the described process are having purity greater than 99.50% and more preferably greater than 99.80% as measured by HPLC.
  • the present invention provides a process to obtain strontium ranelate octahydrate and other hydrates having very less process related impurities, the individual impurities lower than 0.2 % and more preferably lower than 0.1 % , and total impurities lower than 0.5% and more preferably lower than 0.2% as measured by HPLC.
  • the present invention provides a process to obtain strontium ranelate octahydrate and other hydrates having very negligible residual solvent impurities or organic volatile impurities which are lower than ICH norms.
  • the present invention provides an improved process for the preparation of amino diester of formula-ll, which comprises,
  • step b) heating the reaction mixture obtained in step a) to form triethylamine complex of formula-VI I in situ.
  • Yet another embodiment of the present invention wherein the organic solvent is used in reaction of dimethyl 3-oxoglutarate, malononitrile and triethylamine is selected from a C C 4 alcohol, such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, ketones such as acetone, methyl isopropyl ketone, methyl isobutyl ketone and mixtures thereof, preferably methanol.
  • a C C 4 alcohol such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, ketones such as acetone, methyl isopropyl ketone, methyl isobutyl ketone and mixtures thereof, preferably methanol.
  • Yet another embodiment of the present invention further involves compound of complex of methyl 3-(dicyanomethylene)-5-hydroxy-5-methoxy-4-pentenoate with triethylamine formed in situ is reacted with sulfur without isolating the triethylamine complex to provide an amino diester of formula-ll.
  • Another embodiment of the present invention provides process for the preparation of the tetra methyl ester of formula-Ill, which comprises,
  • step a) of reaction of compound of methyl 5-amino-4-cyano-3-(2-methoxy-2-oxoethyl)-2-thiophenecarboxylate with methyl bromoacetate is carried out in an organic solvent in presence of an inorganic base and a catalyst-cetrimide, a C-
  • the reaction is carried out at reflux temperature, about 80-82°C followed by isolation of a compound of formula-Ill,
  • organic solvent used in the reaction of methyl 5-amino-4-cyano-3-(2-methoxy-2-oxoethyl)-2-thiophenecarboxylate and methyl bromoacetate is selected from a C C 4 alcohol, such as methanol, ethanol, n- propanol, isopropanol, n-butanol, isobutanol, tert-butanol, ketones such as acetone, methyl isopropyl ketone, methyl isobutyl ketone and the nitriles such as acetonitrile and the mixtures thereof, preferably acetonitrile.
  • a C C 4 alcohol such as methanol, ethanol, n- propanol, isopropanol, n-butanol, isobutanol, tert-butanol, ketones such as acetone, methyl isopropyl ketone, methyl isobutyl ketone
  • Yet another embodiment of the present invention wherein the inorganic base used in reaction of methyl 5-amino-4-cyano-3-(2-methoxy-2-oxoethyl)-2-thiophenecarboxylate and methyl bromoacetate is selected from sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, preferably potassium carbonate.
  • In one embodiment of the present invention provides preparation of strontium ranelate octahydrate of formula-la by hydrolyzing the tetraester of formula-lll.
  • Another embodiment of present invention provides process for the preparation of strontium ranelate, octahydrate of formula-la, which comprises: a) addition of tetraester of formula-lll to the strontium hydroxide in an aqueous medium,
  • step b) heating the reaction mass obtained in step a) about 100 -102°C,
  • Yet another embodiment of the present invention provides process for preparation of strontium ranelate tetrahydrate of formula-lb, which comprises: a) addition of strontium ranelate octahydrate of formula-la into the isopropanol, b) heating the reaction mass obtained in step a) at about 80 - 85°C,
  • Yet another embodiment of the present invention provides process for the preparation of strontium ranelate monohydrate of formula-lc, polymorph form, which comprises; a) charging of strontium ranelate octahydrate in to a rotocone vacuum dryer, b) heating the product preferably at 95 -100°C under vacuum,
  • One embodiment of the present invention provides a process to obtain a new polymorphic Form-F of crystalline strontium ranelate monohydrate in well defined crystalline form which can be reproduced.
  • Another embodiment of the present invention relates to strontium ranelate octahydrate characterized by a water content of about 22.50 wt.% measured by LOD.
  • the octahydrate of strontium ranelate has a water content of about 21.0 wt.% to about 23.50 wt.%.
  • Another embodiment of the present invention relates to strontium ranelate tetrahydrate characterized by a water content of about 12.21 wt.% measured by LOD.
  • the tetrahydrate of strontium ranelate has a water content of about 11 .0 wt.% to about 13.0 wt.%.
  • Another embodiment of the present invention relates to a new crystalline Form-F of strontium ranelate monohydrate characterized by a water content of 3.65 wt.% measured by TGA.
  • the monohydrate of strontium ranelate has a water content of about 2.50 wt. % to about 5.0 wt.%.
  • Another embodiment of the present invention relates to a new crystalline Form-F of strontium ranelate monohydrate characterized by a water content of 3.68 wt.% measured by LOD.
  • the monohydrate of strontium ranelate has a water content of about 2.5% to about 5.0 wt.%.
  • the crystalline strontium ranelate octahydrate of the present invention having characteristic X-ray powder diffraction pattern is shown in Figure-1 and peak values are shown in table-l.
  • the crystalline Form-F of strontium ranelate monohydrate of the present invention having characteristic X-ray powder diffraction pattern, shown in Figure-3, having peaks with the following characteristic peak values (2 ⁇ ): 26.82, 25.59, 27.29, 9.29, 16.34, 10.48, 13.32, 17.41 , 18.54, 24.74, 29.08, 29.59, 33.00, 35.12 and 13.77 ⁇ 0.2.
  • the crystalline Form-F of strontium ranelate monohydrate has an X-ray powder diffraction pattern corresponding to Figure-3 the diffraction angles and the relative intensities are given in the table-Ill.
  • Example-1 Process for the preparation of methyl 5-amino-4-cvano-3-(2-methoxy-2- oxoethyl)-2-thiophenecarboxylate of formula-ll:
  • Example-2 Process for the preparation of methyl 5-fbis(2-methoxy-2- oxoethyl) amino1-4-cvano-3-(2-methoxy-2-oxoethyl)-2-thiophenecarboxylate of formula-Ill:
  • Acetonitrile (700 ml), potassium carbonate (95.13 g), compound of formula-ll (100 g), cetrimide (4.0 g) and methyl bromoacetate (132.24 g) were charged in to a round bottom flask and heated at 80-82°C for 4 hours. Later reaction mass was cooled to 25-30°C and filtered the inorganic salts, the filtrate was concentrated to give crude product, which was crystallized from methanol, filtered and dried to furnish pure title compound.
  • Strontium hydroxide (153.50 g), DM water (3500 ml) and the compound of formula-Ill (100 g) were charged in to a round bottom flask and heated at 100°C-102°C for 12 hours. Reaction mass was cooled and filtered the product. The product was taken in to aqueous isopropanol, heated for 2 hours, filtered and dried to obtain pure title product
  • Example-4 Process for the preparation of strontium ranelate tetrahvdrate of formula-
  • Strontium ranelate octahydrate (100 g) and isopropanol (600 ml) were charged in to a round bottom flask and heated at 80-85°C for 2 hours. Cooled the reaction mass to room temperature, filtered the material and dried at 60-65°C for 4 hours to give title compound of formula lb.
  • Example-5 Process for the preparation of strontium ranelate monohydrate, Form-F of formula-lc:
  • Strontium ranelate octahydrate 150 g was charged into a rotocone vacuum dryer and heated at 95°C-100°C for 25 hours under vacuum. Then dryer is cooled to room temperature and material is collected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé amélioré pour la préparation d'hydrates de ranélate de strontium purs (Ia-c) en utilisant les intermédiaires, amino diméthyl ester (II) et tétraméthyl ester (III), qui sont préparés par de nouveaux procédés. La présente invention concerne également une nouvelle forme polymorphe cristalline de la forme monohydratée de ranélate de strontium F, et un procédé pour sa préparation. Formules (Ia-c) : Ia- ranélate de strontium octahydraté : n = 8 Ib- ranélate de strontium tétrahydraté : n = 4 Ic- ranélate de strontium monohydraté : n = 1 formule (II) et formule (III).
PCT/IB2012/052645 2012-05-25 2012-05-25 Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée WO2013175270A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/052645 WO2013175270A1 (fr) 2012-05-25 2012-05-25 Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/052645 WO2013175270A1 (fr) 2012-05-25 2012-05-25 Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée

Publications (1)

Publication Number Publication Date
WO2013175270A1 true WO2013175270A1 (fr) 2013-11-28

Family

ID=49623230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/052645 WO2013175270A1 (fr) 2012-05-25 2012-05-25 Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée

Country Status (1)

Country Link
WO (1) WO2013175270A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029036A1 (fr) * 2002-09-24 2004-04-08 Les Laboratoires Servier Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
WO2010021000A2 (fr) * 2008-08-22 2010-02-25 Glenmark Generics Limited Procédé de préparation de ranélate de strontium
WO2010034806A1 (fr) * 2008-09-29 2010-04-01 Ratiopharm Gmbh Formes anhydrates et hydrates de ranélate de strontium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029036A1 (fr) * 2002-09-24 2004-04-08 Les Laboratoires Servier Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
WO2010021000A2 (fr) * 2008-08-22 2010-02-25 Glenmark Generics Limited Procédé de préparation de ranélate de strontium
WO2010034806A1 (fr) * 2008-09-29 2010-04-01 Ratiopharm Gmbh Formes anhydrates et hydrates de ranélate de strontium

Similar Documents

Publication Publication Date Title
US10035802B2 (en) Solid state forms of ibrutinib
US8153801B2 (en) Process and intermediates for preparing integrase inhibitors
US11427570B2 (en) Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
EP3386945A1 (fr) Formes solides d'ester éthylique d'acide (2r,4s)-5-(biphényl-4-yl)-4-[(3-carboxypropionyl)amino]-2-méthylpentanoïque, ses sels et son procédé de préparation
WO2015040640A2 (fr) Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
WO2017221189A1 (fr) Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
NO342907B1 (no) Fremgangsmåte og mellomprodukter for fremstilling av integraseinhibitorer
EP1693368A1 (fr) Procédé pour la préparation de Montelukast
WO2017108960A1 (fr) Procédé de production de composés fumarate de monométhyle
EP2935266A1 (fr) Procédé amélioré pour la préparation de linagliptine
WO2009067856A1 (fr) Inhibiteur de l'histone désacétylase, composition et utilisation de celui-ci
JP2018518489A (ja) アプレミラスト及びその中間体の調製方法
WO2014020555A2 (fr) Procédé amélioré de préparation d'étexilate-mésylate de dabigatran
RU2402532C2 (ru) Способ получения монтелукаста и соединения для его осуществления
RU2436773C2 (ru) Способ получения натриевой соли 1-[[[(r)-m-[(е)-2-(7-хлор-2-хинолил)винил]-альфа-[о-(1-гидрокси-1-метилэтил)фенетил]бензил]тио]метил]циклопропануксусной кислоты
JP2015044856A (ja) ビフェニルイミダゾール化合物の調製方法
WO2013175270A1 (fr) Procédé amélioré pour la préparation d'hydrates de ranélate de strontium et nouvelle forme polymorphe monohydratée
EP2328884A2 (fr) Procédé de préparation de ranélate de strontium
JP2009518380A (ja) ２−クロロエトキシ−酢酸−ｎ，ｎ−ジメチルアミドの製法
WO2015131405A1 (fr) Composé intermédiaire pour la préparation de rosuvastatine calcique et procédé de préparation de rosuvastatine calcique à partir de celui-ci
US20150225376A1 (en) Efficient Process for the Preparation of Lapatinib and Salts thereof by Means of New Intermediates
SK13542003A3 (sk) Spôsob chlórmetylácie tiofénu
JP3467265B2 (ja) アゼチジノン化合物の結晶
EP2828251B1 (fr) Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide
US20110281928A1 (en) Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12877397

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12877397

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 12877397

Country of ref document: EP

Kind code of ref document: A1